Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.
about
The Role and Application of Sirtuins and mTOR Signaling in the Control of Ovarian FunctionsJudicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and PerspectivesPreclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer.The target therapy of ovarian clear cell carcinoma.Integrated copy number and expression analysis identifies profiles of whole-arm chromosomal alterations and subgroups with favorable outcome in ovarian clear cell carcinomas.The promise and challenge of ovarian cancer models.Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma.MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53.Characterization of TP53 and PI3K signaling pathways as molecular targets in gynecologic malignancies.Putative tumor suppression function of SIRT6 in endometrial cancer.Paeonol enhances the sensitivity of human ovarian cancer cells to radiotherapy-induced apoptosis due to downregulation of the phosphatidylinositol-3-kinase/Akt/phosphatase and tensin homolog pathway and inhibition of vascular endothelial growth factRaptor mediates the antiproliferation of cardamonin by mTORC1 inhibition in SKOV3 cells.Integrative kinome profiling identifies mTORC1/2 inhibition as treatment strategy in ovarian clear cell carcinoma.Therapeutic significance of targeting survivin in cervical cancer and possibility of combination therapy with TRAIL.
P2860
Q28066925-0CE58960-693E-4140-8687-6CA05B6A9BB3Q28071388-36CB1D8F-1F74-4E6A-A041-FF82BE7BFDEEQ33591658-0C05045A-1BF2-468B-B679-FF0C17CE29D9Q33598001-ED183694-E128-4252-BD03-F111304C8118Q34274069-4F182DF8-209B-4744-9FB6-9640F9DE9903Q35652910-3BFE36E9-DFFA-4B75-ADAC-B4127A318ECFQ35771750-C136FAAE-EB91-4F70-9358-1B5FFD275184Q36178605-4EC83AF8-26EC-4777-BF30-062656A57D13Q37688946-4BBFD2BB-408C-411C-87F9-6C7ABDCFA5BCQ38812141-59271805-1C3C-43C3-A49F-7FF32FB274B8Q38852078-931BF0B9-9781-4663-A63B-1C73A1CC0BA7Q41623770-E9CF56C1-7B7B-443A-9ACE-BE3BCDFD7365Q50231785-F232F972-924D-45ED-8582-5727A7253B7BQ52717288-9EA90C3F-276C-4F2A-9564-72D7C7BB4FBBQ52724810-105ECCEB-1872-4035-9F7B-31D8154DCA5C
P2860
Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antitumor activity and inducti ...... l PI3K/mTOR inhibitor DS-7423.
@en
Antitumor activity and inducti ...... l PI3K/mTOR inhibitor DS-7423.
@nl
type
label
Antitumor activity and inducti ...... l PI3K/mTOR inhibitor DS-7423.
@en
Antitumor activity and inducti ...... l PI3K/mTOR inhibitor DS-7423.
@nl
prefLabel
Antitumor activity and inducti ...... l PI3K/mTOR inhibitor DS-7423.
@en
Antitumor activity and inducti ...... l PI3K/mTOR inhibitor DS-7423.
@nl
P2093
P2860
P1433
P1476
Antitumor activity and inducti ...... al PI3K/mTOR inhibitor DS-7423
@en
P2093
Aki Miyasaka
Chinami Makii
Frank McCormick
Hiroyuki Aburatani
Kanako Inaba
Katsutoshi Oda
Kei Kawana
Keiko Shoji
Kenbun Sone
Michihiro Tanikawa
P2860
P304
P356
10.1371/JOURNAL.PONE.0087220
P407
P577
2014-02-04T00:00:00Z